41 research outputs found

    Youth-Song

    Get PDF

    Solitude

    Get PDF

    Exile Vol. VI No. 1

    Get PDF
    EDITORIAL 4-6 Ride Through a Mad November Night (story) by Denny Trudell 7-17 Have You Ever Killed Anyone? (poem) by William Bennett 17 State 4 (woodcut) by Pat Wagenhals 18 Deserts (poem) by Chris Condit 19 Ode to a Sleeping Beauty (poem) by Bob Canary 20-29 O Let Me Let the Wild Bird Free (poem) by Chris Condit 30 Undercurrent (poem) by Bob Wehling 30 Afternoon (etching) by Judy Higgins 31 Operation Dump (story) by Christine Onufrock 32-43 Thru the Ages (woodcut) by Dave Bingham 43 Crude Are the Events (poem) by William Bennett 44 Awarded the semi-annual EXILE-Denison Bookstore Writing Prize: Ride Through a Mad November Night by Denny Trudell 7-1

    Exile Vol. VI No. 2

    Get PDF
    EDITORIAL 4-5 Clearing in the Forest (woodcut) by Raymond Berger 6 Haiku (poems) by Jean Ludwig 7 Four in Another Punchbowl (story) 8-15 Untitled (etching) by Patricia Wagenhals 16 Staggering Sky (poem) by Robert Canary 16 Song (poem) by Christine Condit 17 Quadrangle (poem) by James Gallant 18-19 P Stands for Pole (story) by Lee Cullen 20-30 The Beachcomber (poem) by William Bennett 31 Harvest in Kansas (poem) by James Gallant 32 Awarded the semi-annual EXILE-Denison Bookstore Writing Prize: P Stands for Pole by Lee Cullen 20-3

    Exile Vol. V No. 2

    Get PDF
    EDITORIAL 4-6 Jamais (poem) by Iris Carroll 6 The Minister\u27s Narcissus by Julia Santucci 7-18 DRAWING by Anne Irgens 12 Solitude (poem) by Christine Condit 18 Island Lady\u27s Bill-Green Sky (poem) by Robert Wehling 19 Looking for Enchantment (poem) by Dennis Trudell 19 Silence (woodcut) by Carol Wilson 20 Saturday Night (story) by Ed Grimm 21-25 On Unemployment (poem) by William Bennett 25 Atlas (poem) by Bob Canary 26 A Psychology of Confrontation (essay) by Barbara Haupt 27-35 Urban (woodcut) by Carol Wilson 36 The Way They Make Guys (story) by Dennis Trudell 37-38 This story [ The Minister\u27s Narcissus ] by Julia Santucci has been awarded the semi-annual EXILE-Denison Bookstore creative writing prize. (pg 18

    Exile Vol. V No. 1

    Get PDF
    EDITORIAL 4 Not a Care in the World (story) by Lauretta Millikin 7-9 Youth-Song (poem) by Christine Condit 10 The Other Side of Light (story) by William Bennett 11-19 The Tide Sweeps Sand (poem) by Carol Ann Schreier 19 1865 (poem) by Dennis Trudell 20 Metaphysics (poem) by Joseph Arnold 20 Petit Aquarium (poem) by André Winandy 21 One Summer Morning (story) by Marilyn Ruff 22-29 Forgetting (poem) by William Bennett 29 DRAWING by Anne Irgins 30 November Morning (poem) by Joseph Arnold 31 Technicolor Days (poem) by Dennis Trudell 32 Kiddie Cocktails (story) by Julia Santucci 33-42 San Joaquin Valley (poem) Dennis Trudell 42 DRAWING Cathy Thompson 43 In this issue the editors of EXILE are proud to publish The Other Side of Light by William Bennett. This story has been awarded the semi-annual Denison Book Store - EXILE Creative Writing Priz

    The interspecific growth–mortality trade-off is not a general framework for tropical forest community structure

    Get PDF
    Resource allocation within trees is a zero-sum game. Unavoidable trade-offs dictate that allocation to growth-promoting functions curtails other functions, generating a gradient of investment in growth versus survival along which tree species align, known as the interspecific growth–mortality trade-off. This paradigm is widely accepted but not well established. Using demographic data for 1,111 tree species across ten tropical forests, we tested the generality of the growth–mortality trade-off and evaluated its underlying drivers using two species-specific parameters describing resource allocation strategies: tolerance of resource limitation and responsiveness of allocation to resource access. Globally, a canonical growth–mortality trade-off emerged, but the trade-off was strongly observed only in less disturbance-prone forests, which contained diverse resource allocation strategies. Only half of disturbance-prone forests, which lacked tolerant species, exhibited the trade-off. Supported by a theoretical model, our findings raise questions about whether the growth–mortality trade-off is a universally applicable organizing framework for understanding tropical forest community structure

    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Get PDF
    Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline
    corecore